Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Will Leandro comprehensively discuss the company's metaverse app planned development, meta bridging, & platform integrations? An isolated mall with even a few dozen storefronts is comparable with a nearly indistinguishable muon on the cosmic microwave background.
When generically asked about TuVolten dealer locations in Dallas, Los Angeles, & Miami, the IQSTel NPC responded by saying "we have authorized dealers in those locations. Please provide your location so I can find the right dealer"
The audio grid map for the app needs to tighten & be adapted to the device with which it is being accessed. I'd rather here mall music until I prompt for assistance or information. Bandwidth limitations suggests the app remains in prelaunch to match the necessity for careful use of cash reserves. I hope they are negotiating a news driven ascended funding plateau from which they can be provide with the believable $10 million in additional cash needed for their outlined FY 2023 business development goals.
No! They are the people who withdrew their talent from mspc when it became apparent that its market potential was impotent, then it subsequently failed.
Does the new S-1/A entail the termination of the secondary VWAP option with Apollo? I only see discussion of the renderable for short sell 4,800,000 primary option acquired by Apollo for an upfront $500,000 & the statement that management will be selling 10 million shares on the open market highlighted.
Q3 is half over. Relatively speaking, with so little time left in year news on fintech and ev bike sales must be imminent. The usage of "soon" (this q?) & "longterm" (q4?) must be significant.
This smells like a note that will be converted into preferred shares to maintain voting control
To post a $1 million net profit for 2023, IQST must wash out the $363,000 reported 1st quarter loss. It makes since to expect the company to post a net profitable quarter which breaks them even for the year if you believe their yearly net profit will exceed $1 million.
If they begin their filing today, will they preview these data points today?
Your disinformation campaign is wasting space. My original points stand untarnished. Apollo isn't in the business of hurting the companies it finances. In fact, its vast financial network outreach has made it into a matchmaker for companies aspiring for synergistic growth. They were never going to exceed ownership reporting requirements, because to do so would entail them buying worthless (even when heavily discounted) stock that could not cover their business costs.
The >=5% & >=10% contract provisions with Apollo are related to 13D/ 13G reporting requirements for 5% and Form 3, 4, 5 reporting requirements for 10% ownership stake ....
The Holder, upon not less than 61 days’ prior notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Option held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Company.
🙄There is no provision in that contract prohibiting Apollo from owning more than 4.99%. You are referring to the 13D 10 day reporting requirement threshold on >=5% ownership stake. Until Apollo files a 13D (or quarterly 13F), IQST is only capable of knowing that Apollo had (though it may continue to possess) the shares it sold to them under the terms of their funding contract, as such it must report their current ownership stake as 0 until Apollo says "No. Here is our 13D. We own 5% or more of IQST"🙄 13 Fs are due 45 days after reported Quarter ends, but are a different matter
So far the VWA over the last week suggests the 2 million shares acquired by Apollo were made at .27 - (32%) discount= .1846 which is substantially greater than .136. The point I was making & which was realized by all other readers is that Apollo could have exercised its option in its entirety at a much cheaper price, but, in so doing, it would be flooding a weak shareholder base with worthless shares from a funding transaction with IQST that would not abet the company's plan to improve its balance sheet through inorganic & organic growth. It is on this point, as a profit focused intermediary, that Apollo's vast analytics for its inter-business financial networking is critical in determining whom, how, when, & why it chooses to provide funding services to companies
I've had a great day, so am generously sharing remedial instruction with a widely acknowledged intolerable fool.
1) why didn't Apollo exrcise options at 10 cents? Buying paper at a discount does not cover commissions, account handling & other business & legal costs for apollo & its 29 offices around the world, including Miami. Apollo only buys paper (stock) after it has created the conditions in which it will profit beyond account manager commissions upon it. You have 24 hours to admit your mistakes or I will routinely mock your poor comprehension & lack of reasoning skills until it no longer amuses me.
Until this telecom has a positive P/E, it will not have enough shareholders to sustain a fair market valuation. Now, it could be that Apollo & IQST are working on an acquisition for the company, but have agreed to fund its purchase with a large bounty of an agreed share total discounted before an anticipated & authentically newsworthy catalyst. If so, then I'd expect Apollo to defend that initial option exercise price point until it has its expected pre-event stake. In this hypothesis, the remaining shares would be purchased after the price spike post catalyst & the entire lot subsequently sold at profit once the acquisition is finalized.
Does the OS increase affect the likelihood of net profitability being reported with the Q? Why would IQSTel need $500,000? With 3 weeks to go before the Q, should we expect additonal OS increases?
IOT labs 4Q2022 revenue was approximately 13.5 million. Its 1Q2023 revenue was 15.26 million. Is this an indication of increased SmartTank usage by BASF. How much of the preliminary 2q2023 rapid revenue is attributable to the fulfillment of the late june 2022 SmartTank MOU for field test installation? Is the MOU open-ended, meaning without usage quotas or is it reasonable to expect an imminent declaration on its formalization or, as made extremely unlikely by IOTlabs increasing revenues, its cancellation?
"Lower your expectations" is a dumb mantra. If you are going to ride Lady Fortune, you do it until she throws you off. IQST has been ticking off financial & trusting (deal contingent) relationship checkboxes for a nasdaq uplifting run for more than 2 years. If they dubiously haven't done that by now, then their growth would not be accelerating. I am thus reasserting that the most likely spark for the big run is BASF & IOT news that establishes the company's worth to the Fortune 500 community. BASF needs to implement cost savings to satisfy institutional investors dividend expectations.
Amid weakened, but stabilizing, demand BASF will report revenue declines & they will reduce dividends duringr the 2h23. Will they ever contractually fully deploy Smart Tank & SmartGas to verify the cost-cutting but efficiency improving value of these products? If so, then you'd think the very near term would be the optimum period for effecting changes intended to enhance bottom line improvements in 2024.
[Corrected] Anticipation for a measurable P/E ratio imho should factor into the share price over the next 4 weeks. .39-.49 cents is a safe zone for market speculators to address q2 financials. If profitable, it will take no more than a few days to plateau & subsequently hover around $1 until other catalysts, events, or agreements weigh in.
Don't confuse the sentiments of others or yourself with graphed high school business math if you are just going to make untidy & simplistic opinions known. Language skills & business acumen are much more effective (especially when you are not prone to mistaking an SEC prospectus or shelf registration for a much more comprehensive & legally binding contract dependent upon strict accounting)
Anticipation for a measurabe P/E ratio imho should factor into the share price over the next 4 weeks. .39-.49 cents is a safe zone for market speculators to address q2 financials. If profitable, it will take no more than a few days to plateau & subsequently hover around $1 until other catalysts, events, or agreements weigh in. ...See...You shouldn't to confuse the sentiments of others or yourself with graphed high school business math to make untidy & simplistic opinions known. Language skills & business acumen are much more effective (especially when you mistake an SEC prospectus or shelf registration for a much more comprehensive & legally binding contract dependent upon strict accounting
You are confusing the filing with the contract signed with Apollo. Apollo isn't simply unconcerningly providing money for shares; it is funding detailed spending. The Apollo financial officer overseeing the contracted account must obtain approval from senior partners/upper management for additional purchases & they want details on how that money will be used [no keg parties]. In the filings this is covered under management's selling authority
Look again. I think Apollo paid for the 4.8 million option in exchange for the obligation to buy fixed amounts in late '22 & early '23 with the remaining being up to the company (As they mentioned in subsequent PRs).
Will the shocking 32% [$8 million, relatively speaking, is alot] q1 to q2 revenue growth transact net profitability when Q report is released in nearly 30 days? As I read the S-1/A, the company with begrudgingly brusque confidence does not like the fact that the remaining vwap shares that can be exercised will not match the projected $10 million in growth costs & that as a result they anticipate, if need be, seeking other financing for those objectives. Napkin math says that at best if the .13 vwap is realized with a just in case desperation act to exercise remaining options then the company would obtain less than $3 million by September 30th, 2023. In short, there is no reason to sell until the Q is released. The company isn't exercising the remaining options if they have a net profit which will land them a better deal
Why wouldn't they include an EVOSS Kiosk & the bikes in the metaverse app? In order to tap into the digital retail potential of the metaverse company product related offerings are necessary. If they are only relying upon the sale of phones & money services then the revenue potential is very limited (much less than $1million) because there are easier ways to conduct those one off transactions.
I am a concerned that mgmt may again waft desperation & undermine SP by releasing preliminary numbers to appease despairing shareholders.
This may be the fluffiest PR yet & I am saying that as one of the longest of longs whose position is still up 80%. The app features two store fronts (IQST & Apple) but without really detailed product listings. Many more store fronts are needed & likely will be added in the ensuing months as commission agreements are reached, but if we are being honest it is the LatAm IQSTel customer base that will primarily be utilizing the app. This presupposes preinstallation on all purchased devices on new accounts....In addition, there has been talk of a new acquisition. The current price spike signals that the company will tap into Apollo options agreement & its noisome share weighting to pay for it. Ideally this takes place before the Q is released in mid August to prime the real price run.
Assessing the full ramifications of collected data does not equal manipulating data. Low risk patients are always inherent in any treatment protocol. Distinguishing & expansively accounting for the precise microcellular environment conditions responsible for positive & negative responses are of paramount interest to the FDA, NIH, & their global equivalents because complete data valuably contributes to all treatments & future cancer research.
As such, it is already a foregone conclusion that the BLA will be approved. Whether PDUFA is granted to cel-sci for the "It-Matters" study or not does not foreclose, future approval of Multikine as long as it is an incontrovertibly effective treatment option for non-trivial portion of, at present, squamous cell sarcoma paitents
I do forsee bp to expect legwork for accelerated approval based confirmatory trials studying Multikine's effectiveness in melanoma, breast cancer, etc to be packaged as sweetners for the deal
How does a CEO allay concerns about insider trading on the prospect for a buyout!/(JV)? He does it by openly stating that his company isn't positioned to provide the deserved market wherewithal to fully support the widespread adoption & use of his company's product. He then further qualifies his expectations by assuring audiences that the company no longer needs to raise funds to support the development of any of its products. All of this begs the question "Will we even see the (undoubtedly finished) 10K before an overshadowing announcement is made?"
Sounds reasonable. No one would be surprised to learn, however, which financial entity actually controls the 212 app or how easy it was for them to game trading advantages of listed holding companies which it financed on 212 & similarly controlled platforms when monetary policy & money supply favored loose OS structure.
If IQST does not tighten its share structure within the next few months, then we will know that Apollo has decided not to prioritize its growth by the quick & full exercise of its"master fund"
Even before the offerings, share structure has proven to be too loose for a recession. During the last year IQST has shed 75% of its value & 90% iover the last 22 months. Things will not improve until share structure is tightened to match market conditions. A reverse split is the company's only option.
There is no real stock price buoyancy difference between your claimed 166 million OS & the discounted ~185 million total I am justifying the need for a RS with.
Or maybe the involved trading houses low-level employees are too inflexible to ply their methods with other emerging companies in a more difficult trading environment, so they intend to cling desperately to sham pennies that will starve IQST of real opportunities.
You do know that when I have time later I will post the amended table & schedule right? & be discussing market positioning & lessons from ALPP (which is also facing a RS)
A RS is not a scam when it is done by a company projecting 9 figure earnings to address its need for share price traction to gain access to institutional investors & escape flim flam sourcing for working capital.
So you are de-emphasizing the discount formula which allows Apollo to obtain shares at about .16 for the current price with scheduled pay $480,000 by dates totalling 3.8 million that I am adding to the 10 million sell at best price shares being offered by. IQST.
A RS by year end or to start 2023 likely favors $IQST shareholders if the company can properly stack news. The recent offering will increase OS by about 32 million shares & provide the company about 6 million in total cash (It is practical for Apollo to exercise all option conditions now & for the company to sell shares on reported consistencies). Furthermore, the release of fantastic news by a company with 190 million OS that is projecting/substantiating 90 million in revenue will not move share price more than a nickel because of the necessary selling & other investment market pricing pressures. Nevertheless, we can feel safe in knowing that the continuing .24-.29 price range is the bottom & is an excellent buying opportunity for those counting on a 1/4 or 1/5 RS to allow the best expected news to make the share price sustainingly exceed Nasdaq compliance.
Any prognostication about the pre-BLA that alleges CVM investor relations as a source is an act of deception relying upon presumptions about the 60 day calendar for an agreed & approved scheduling of the pre-BLA by the FDA. Included within the 60 day pre-BLA calendar is a 21 day window for the scheduled meeting notice letter to arrive. As such, it is wrong to discount CVM's pre-BLA occurring during 2022 until after Thanksgiving. Moreover, investor relations would never be made party to negotiations between CVM & the FDA until SEC reporting required material events happen, because leaks are too litigiously expensive.
Your $12B expectation is ridiculous & unrealistic. The wide use window for Multikine isn't long enough. Cutting edge understanding of cancer cellular dynamics are currently finding expression in clinical trials. In addition, it will take time to erode Keytruda's market share (after additional small scale alternative use clinical trials for Multikine). I expect an accepted buyout offer to ranger from 3-6B.
Does no Pre-BLA = Buyout? Does the prospect of ownership change unnecessarily complicate FDA review of major filings? It is reasonable to expect that any BP would want to minimize time costs between purchase & FDA review